---
schema_version: "secwatch.filing_event.v1"
accession: "0001804220-22-000013"
form_type: "8-K"
ticker: "REGN"
cik: "0000872589"
company_name: "REGENERON PHARMACEUTICALS, INC."
filed_at: "2022-05-04T23:59:59+00:00"
generated_at: "2026-06-26T01:04:05.708121+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Regeneron Q1 revenue up 17% to $2.97B; non-GAAP EPS $11.49, GAAP EPS $8.61; Dupixent +43%

## Summary
- Total revenue $2.97B (+17% YoY); ex-REGEN-COV revenue +25%; GAAP net income $974M, diluted EPS $8.61.
- Non-GAAP net income $1.32B, diluted EPS $11.49 (+16% YoY); free cash flow $1.96B.
- EYLEA U.S. net sales $1.52B (+13%); Dupixent global net sales $1.81B (+43% as recorded by Sanofi).
- R&D guidance raised to $3.27-$3.50B (GAAP), $2.90-$3.10B (non-GAAP); SG&A guidance unchanged.
- REGEN-COV inventory write-offs $58M in COGS; $211M unrealized losses on equity securities; EUA revised.

## SEC filing metadata
- accession: 0001804220-22-000013
- form_type: 8-K
- ticker: REGN
- cik: 0000872589
- company_name: REGENERON PHARMACEUTICALS, INC.
- filed_at: 2022-05-04T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/872589/000180422022000013/0001804220-22-000013-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/872589/000180422022000013/regn-20220504.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001804220-22-000013
- JSON: https://secwatch.observer/filing/0001804220-22-000013.json
- Plain text: https://secwatch.observer/filing/0001804220-22-000013.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.